Go or no go? Pdufa resolutions eyed for J&J and Amryt
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Reata rout leaves next project in doubt
Bardoxolone looks dead after yesterday’s adcom vote, but what about omaveloxolone?
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
